Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Astellas pays Aveo $125mm up front for rights to tivozanib; deal terminated

Executive Summary

Astellas Pharma Inc. has licensed exclusive worldwide rights outside of Asia to develop, manufacture, and sell oncology company's Aveo Pharmaceuticals Inc.’s Phase III cancer compound tivozanib. The Japanese pharmaco paid $125mm up front, a fee that includes $50mm for ongoing R&D.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies